Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

Protocol: Alliance – A151804

SCHEMA A151804

Please Note:  Below is a partial list of eligibility, please contact Genesys Hurley Cancer Institute, Research Department at (810) 762-8181, (810) 762-8079 or (810) 762-8038 to discuss the full list of eligibility requirements.  Thank  you!

Eligibility:

1. Received a regimen containing one or more immuno-oncology therapeutics.
2. Has not previously been treated with CTLA-4, PD-1 or PD-L1 inhibitors.
3. Experienced one or more serious AEs.